Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1986 Jun;88(2):323–331. doi: 10.1111/j.1476-5381.1986.tb10208.x

Binding of a radioiodinated 13-azapinane thromboxane antagonist to platelets: correlation with antiaggregatory activity in different species.

S Narumiya, M Okuma, F Ushikubi
PMCID: PMC1916831  PMID: 3730697

Abstract

Binding of a 125I-labelled derivative of the 13-azapinane thromboxane antagonist (ONO-11120), [125I]-9,11-dimethylmethano-11,12-methano-16-(3-iodo-4-hydroxyp hen yl)-13, 14-dihydro-13-aza-15-beta-omega-tetranor-thromboxane A2 ([125I]-PTA-OH), to washed platelets of human, dog and rabbit was studied. Results were compared with the in vitro inhibitory potency of ONO-11120 on platelet aggregation induced by arachidonate and a thromboxane agonist, 9,11-epithio-11,12-methano-thromboxane A2 (STA2). [125I]-PTA-OH bound to washed human platelets in a reversible, saturable and temperature-dependent manner, and specific binding displaced by 20 microM ONO-11120 constituted about 40% of the total binding. Scatchard analyses revealed a single class of specific binding and the equilibrium dissociation constant (KD) and maximal concentration of binding sites (Bmax) were 22 nM and 390 fmol per 10(8) platelets (about 2,300 sites per platelet), respectively. In addition to ONO-11120, STA2 and another thromboxane receptor agonist, (15S)-hydroxy-11,9-epoxymethano-prosta-5Z,13E-dienoic acid (U-46619), effectively displaced the binding with IC50 values of 44 and 125 nM respectively. Prostaglandin D2 (PGD2) partially displaced the binding only at a concentration above 1 microM. PGE1 and thromboxane B2 (TXB2) were without effect up to 100 microM. Similar binding of [125I]-PTA-OH was observed on dog platelets. The KD and Bmax were 12 nM and 110 fmol per 10(8) platelets (about 680 sites per platelet), respectively, and these values did not change significantly after adrenaline treatment which potentiated arachidonate-induced aggregation of platelets in this species.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
323

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Armstrong R. A., Jones R. L., Peesapati V., Will S. G., Wilson N. H. Competitive antagonism at thromboxane receptors in human platelets. Br J Pharmacol. 1985 Mar;84(3):595–607. doi: 10.1111/j.1476-5381.1985.tb16139.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Armstrong R. A., Jones R. L., Wilson N. H. Ligand binding to thromboxane receptors on human platelets: correlation with biological activity. Br J Pharmacol. 1983 Aug;79(4):953–964. doi: 10.1111/j.1476-5381.1983.tb10541.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bhagwat S. S., Hamann P. R., Still W. C., Bunting S., Fitzpatrick F. A. Synthesis and structure of the platelet aggregation factor thromboxane A2. Nature. 1985 Jun 6;315(6019):511–513. doi: 10.1038/315511a0. [DOI] [PubMed] [Google Scholar]
  4. Burke S. E., Lefer A. M., Nicolaou K. C., Smith G. M., Smith J. B. Responsiveness of platelets and coronary arteries from different species to synthetic thromboxane and prostaglandin endoperoxide analogues. Br J Pharmacol. 1983 Feb;78(2):287–292. doi: 10.1111/j.1476-5381.1983.tb09393.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cooper B., Ahern D. Characterization of the platelet prostaglandin D2 receptor. Loss of prostaglandin D2 receptors in platelets of patients with myeloproliferative disorders. J Clin Invest. 1979 Aug;64(2):586–590. doi: 10.1172/JCI109497. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Corey E. J., Narasaka K., Shibasaki M. A direct,stereocontrolled total synthesis of the 9,11-azo analogue of the prostaglandin endoperoxide, PGH2. J Am Chem Soc. 1976 Sep 29;98(20):6417–6418. doi: 10.1021/ja00436a074. [DOI] [PubMed] [Google Scholar]
  7. Halushka P. V., MacDermot J., Knapp D. R., Eller T., Saussy D. L., Jr, Mais D., Blair I. A., Dollery C. T. A novel approach for the study of thromboxane A2 and prostaglandin H2 receptors using an 125I-labeled ligand. Biochem Pharmacol. 1985 Apr 15;34(8):1165–1170. doi: 10.1016/0006-2952(85)90490-3. [DOI] [PubMed] [Google Scholar]
  8. Hamberg M., Svensson J., Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A. 1975 Aug;72(8):2994–2998. doi: 10.1073/pnas.72.8.2994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hung S. C., Ghali N. I., Venton D. L., Le Breton G. C. Specific binding of the thromboxane A2 antagonist 13-azaprostanoic acid to human platelet membranes. Biochim Biophys Acta. 1983 Feb;728(2):171–178. doi: 10.1016/0005-2736(83)90468-6. [DOI] [PubMed] [Google Scholar]
  10. Johnson G. J., Leis L. A., Rao G. H., White J. G. Arachidonate-induced platelet aggregation in the dog. Thromb Res. 1979 Jan;14(1):147–154. doi: 10.1016/0049-3848(79)90033-1. [DOI] [PubMed] [Google Scholar]
  11. Johnson G. J., Rao G. H., Leis L. A., White J. G. Effect of agents that alter cyclic AMP on arachidonate-induced platelet aggregation in the dog. Blood. 1980 May;55(5):722–729. [PubMed] [Google Scholar]
  12. Jones R. L., Peesapati V., Wilson N. H. Antagonism of the thromboxane-sensitive contractile systems of the rabbit aorta, dog saphenous vein and guinea-pig trachea. Br J Pharmacol. 1982 Jul;76(3):423–438. doi: 10.1111/j.1476-5381.1982.tb09236.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Katsura M., Miyamoto T., Hamanaka N., Kondo K., Terada T., Ohgaki Y., Kawasaki A., Tsuboshima M. In vitro and in vivo effects of new powerful thromboxane antagonists (3-alkylamino pinane derivatives). Adv Prostaglandin Thromboxane Leukot Res. 1983;11:351–357. [PubMed] [Google Scholar]
  14. Le Breton G. C., Venton D. L., Enke S. E., Halushka P. V. 13-Azaprostanoic acid: a specific antagonist of the human blood platelet thromboxane/endoperoxide receptor. Proc Natl Acad Sci U S A. 1979 Aug;76(8):4097–4101. doi: 10.1073/pnas.76.8.4097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Lefer A. M., Smith E. F., 3rd, Araki H., Smith J. B., Aharony D., Claremon D. A., Magolda R. L., Nicolaou K. C. Dissociation of vasoconstrictor and platelet aggregatory activities of thromboxane by carbocyclic thromboxane A2, a stable analog of thromboxane A2. Proc Natl Acad Sci U S A. 1980 Mar;77(3):1706–1710. doi: 10.1073/pnas.77.3.1706. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Mais D. E., Dunlap C., Hamanaka N., Halushka P. V. Further studies on the effects of epimers of thromboxane A2 antagonists on platelets and veins. Eur J Pharmacol. 1985 Apr 23;111(1):125–128. doi: 10.1016/0014-2999(85)90121-9. [DOI] [PubMed] [Google Scholar]
  17. Mais D. E., Saussy D. L., Jr, Chaikhouni A., Kochel P. J., Knapp D. R., Hamanaka N., Halushka P. V. Pharmacologic characterization of human and canine thromboxane A2/prostaglandin H2 receptors in platelets and blood vessels: evidence for different receptors. J Pharmacol Exp Ther. 1985 May;233(2):418–424. [PubMed] [Google Scholar]
  18. Nicolaou K. C., Magolda R. L., Smith J. B., Aharony D., Smith E. F., Lefer A. M. Synthesis and biological properties of pinane-thromboxane A2, a selective inhibitor of coronary artery constriction, platelet aggregation, and thromboxane formation. Proc Natl Acad Sci U S A. 1979 Jun;76(6):2566–2570. doi: 10.1073/pnas.76.6.2566. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Parise L. V., Venton D. L., Le Breton G. C. Arachidonic acid-induced platelet aggregation is mediated by a thromboxane A2/prostaglandin H2 receptor interaction. J Pharmacol Exp Ther. 1984 Jan;228(1):240–244. [PubMed] [Google Scholar]
  20. Plow E. F., Marguerie G. A. Induction of the fibrinogen receptor on human platelets by epinephrine and the combination of epinephrine and ADP. J Biol Chem. 1980 Nov 25;255(22):10971–10977. [PubMed] [Google Scholar]
  21. Siegl A. M., Smith J. B., Silver M. J. Specific binding sites for prostaglandin D2 on human platelets. Biochem Biophys Res Commun. 1979 Sep 12;90(1):291–296. doi: 10.1016/0006-291x(79)91623-1. [DOI] [PubMed] [Google Scholar]
  22. Svenssen J., Strandberg K., Tuvemo T., Hamberg M. Thromboxane A2: effects on airway and vascular smooth muscle. Prostaglandins. 1977 Sep;14(3):425–436. doi: 10.1016/0090-6980(77)90258-1. [DOI] [PubMed] [Google Scholar]
  23. Svensson J., Hamberg M., Samuelsson B. On the formation and effects of thromboxane A2 in human platelets. Acta Physiol Scand. 1976 Nov;98(3):285–294. doi: 10.1111/j.1748-1716.1976.tb10313.x. [DOI] [PubMed] [Google Scholar]
  24. Wallenstein S., Zucker C. L., Fleiss J. L. Some statistical methods useful in circulation research. Circ Res. 1980 Jul;47(1):1–9. doi: 10.1161/01.res.47.1.1. [DOI] [PubMed] [Google Scholar]
  25. Yoshimoto T., Yamamoto S., Okuma M., Hayaishi O. Solubilization and resolution of thromboxane synthesizing system from microsomes of bovine blood platelets. J Biol Chem. 1977 Aug 25;252(16):5871–5874. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES